GLYCOMIMETICS INC (GLYC) Stock Price, Forecast & Analysis
USA - NASDAQ:GLYC - US38000Q1022 - Common Stock
GLYC Key Statistics, Chart & Performance
The current stock price of GLYC is 0.157 USD. In the past month the price decreased by -37.15%. In the past year, price decreased by -40.3%.
GLYC Latest News, Press Relases and Analysis
GLYC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About GLYC
Company Profile
GlycoMimetics, Inc. is a biotechnology company, which engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm has no ongoing operations, is not performing any research and development, and is preserving cash until the contemplated merger and private placement. The firm was developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation.
Company Info
GLYCOMIMETICS INC
9708 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Rachel K. King
Employees: 4
Phone: 12402431201
GLYCOMIMETICS INC / GLYC FAQ
Can you describe the business of GLYCOMIMETICS INC?
GlycoMimetics, Inc. is a biotechnology company, which engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2014-01-10. The firm has no ongoing operations, is not performing any research and development, and is preserving cash until the contemplated merger and private placement. The firm was developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation.
Can you provide the latest stock price for GLYCOMIMETICS INC?
The current stock price of GLYC is 0.157 USD. The price decreased by -5.42% in the last trading session.
What is the dividend status of GLYCOMIMETICS INC?
GLYC does not pay a dividend.
What is the ChartMill technical and fundamental rating of GLYC stock?
GLYC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of GLYC stock?
GLYCOMIMETICS INC (GLYC) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for GLYCOMIMETICS INC?
GLYCOMIMETICS INC (GLYC) has a market capitalization of 10.13M USD. This makes GLYC a Nano Cap stock.
GLYC Technical Analysis
GLYC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLYC. While GLYC seems to be doing ok healthwise, there are quite some concerns on its profitability.
GLYC Financial Highlights
Over the last trailing twelve months GLYC reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 34.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -341.52% | ||
| ROE | -712.87% | ||
| Debt/Equity | 0 |